AB-801
- Generic Name
- AB-801
A Study of AB801 Monotherapy and Combination Therapy in Participants With Advanced Malignancies
- First Posted Date
- 2023-11-07
- Last Posted Date
- 2025-05-08
- Lead Sponsor
- Arcus Biosciences, Inc.
- Target Recruit Count
- 91
- Registration Number
- NCT06120075
- Locations
- 🇺🇸
Icahn School of Medicine at Mount Sinai/ The Tisch Cancer Center, New York, New York, United States
🇺🇸START - South Texas Accelerated Research Therapeutics, LLC., San Antonio, Texas, United States
🇺🇸Sarah Cannon Research Institute, Denver, Colorado, United States
A Study to Assess the Safety, Pharmacokinetics, and Pharmacodynamics of AB801 in Healthy Volunteers
- First Posted Date
- 2023-08-22
- Last Posted Date
- 2024-08-28
- Lead Sponsor
- Arcus Biosciences, Inc.
- Target Recruit Count
- 32
- Registration Number
- NCT06004921
- Locations
- 🇬🇧
Quotient Sciences - Nottingham, Nottingham, United Kingdom
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath